Infertility
Conditions
Keywords
Ethinyl estradiol, Polycystic ovary syndrome, Intrauterine insemination
Brief summary
According to the studies CC is successful at inducing ovulation in 50%-75% of cases, but only 30-40% becomes pregnant. The difference has been attributed to a negative action of clomifen citrate(CC) in the form of prolonged antiestrogenic effects on endometrial receptivity. For avoiding of these negative effects, giving ethinyl estradiol in sufficient dosages may be effective. The purpose of this study is comparing pregnancy rates after IUI in women who use CC alone and those who use CC in combination with ethinyl estradiol
Detailed description
The proposal of This study approved by our institutional review boards and institution's ethical committee, and all Participants will sign a written consent before enter to study. All patients will be randomly divided into two groups, A and B. Stimulation will begin on day 3 with the administration of 100 mg of clomifen citrate(CC) daily for 5 days. On day 8, ethinyl estradiol will be given daily for 5 days in group A and placebo will be given for 5 days in group B. Plasma levels of estradiol(E2), Luteinizing hormone (LH) and Follicle-stimulating hormone (FSH) will be evaluated on days 3 and 13 of the menstrual cycle. Ultrasound examination will be done on days 3, 13 and days of HCG administration and IUI for determining of endometrial thickness, number of follicles and size of the dominant follicle. When the diameter of at least one follicle reached equal or greater than 18 mm, human chronic gonadotrophin (HCG) 10,000 IU will be administered. The pulsatility index also will be recorded in both uterine arteries on day of HCG administration. A single IUI will be performed 24-36 hours after the administration of hCG. Pregnancy will be confirmed by increasing level of concentration of serum βHCG which will be assessed 14 days after IUI
Interventions
DRUGclomiphene citrate with ethinyl esteradiol
Clomiphene citrate is used in combination of ethinyl estradiol (0.05 mg for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination
DRUGclomiphene citrate with plasebo
Clomiphene citrate is used in combination of placebo (for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination
Sponsors
Royan Institute
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
25 Years to 30 Years
Healthy volunteers
No
Inclusion criteria
* The patients with first treatment cycle * Age between 25 and 30 years, * Infertility for at least 2 years' duration, * Oligomenorrhea or amenorrhea associated with a positive Progesterone challenge test * Women with normal concentrations of prolactin, free thyroxin and thyroid-stimulating hormone (TSH)
Exclusion criteria
* Women whose partners had an abnormal semen analysis according to World Health Organization * Women who had uterine or tubal abnormalities on hysterosalpingography, and women who had a body mass index of \>30 kg/m2.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical Pregnancy rate | 4-6 weeks after embryos transfer(ET) | Usage of clomifen citrate on special days can increase pregnancy rate |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of stimulation days | 5 days | usage of clomiphen citrate with ethyl estradiol in patients with poly cystic ovary can stimulate ovulation |
| Endometrial thickness | 13 days | effect of using drugs to increase endometrial thickness |
Countries
Iran
Outcome results
None listed